The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
Dinutuximab β can be used to treat children with high‐risk neuroblastoma (NB). Due to its high price, whether dinutuximab β is cost‐effective for the treatment of high‐risk NB remains uncertain. Therefore, assessing the cost‐effectiveness of dinutuximab β in children with high‐risk NB is of high importance.
Methods
The health utilities and economic outcomes in children with high‐risk...